Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype
Authors:
Open Access
- 11 September 2024
- journal article
- research article
- Published by Springer Nature in Clinical Epigenetics
- Vol. 16 (1) , 1-5
Abstract
DNA-hypomethylating agents (HMAs) induce notable remission rates in AML/MDS patients withTP53mutations; however, secondary resistance often develops rapidly. In the DECIDER trial (NCT00867672), elderly AML patients (also those with adverse genetics) randomized to all-transretinoic acid (ATRA) added to decitabine (DEC) attained significantly delayed time-to-resistance. An 82-year-old patient with a non-disruptive, in-frameTP53mutation (p.Cys238_Asn239delinsTyr, VAF 90%) and complex-monosomal karyotype attained a complete hematologic and cytogenetic remission with DEC + ATRA, with 3.7 years survival after 30 treatment cycles that were well-tolerated. Further HMA + ATRA studies appear warranted in AML/MDS patients of different genetic risk groups ineligible for more intensive treatment.Trial registration: This trial was registered at ClinicalTrials.gov identifier: NCT00867672Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (FOR2674 A02, FOR2674 A09, FOR2674 A05)
- German Federal Ministry of Education and Research (01KG0913)
- Universitätsklinikum Freiburg
This publication has 15 references indexed in Scilit:
- Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cellsBlood, 2023
- Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNBlood, 2022
- The antileukemic activity of decitabine upon PML/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperationBlood Cancer Journal, 2022
- TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasmsBlood Advances, 2022
- Decitabine Induces Gene Derepression on Monosomic Chromosomes: In Vitro and In Vivo Effects in Adverse-Risk Cytogenetics AMLCancer Research, 2021
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaNew England Journal of Medicine, 2020
- Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II TrialJournal of Clinical Oncology, 2020
- A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignanciesScience, 2019
- Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional careLeukemia, 2018
- Evolutionary Action Score ofTP53Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck CancerCancer Research, 2015